The response, operability, and type of surgery following neoadjuvant chemotherapy in Sudanese patients with locally advanced breast cancer by Mohamed, Abdelsamie Abdalla et al.
Sudan Journal of Medical Sciences
Volume 13, Issue no. 3, DOI 10.18502/sjms.v13i3.2961
Production and Hosting by Knowledge E
Research Article
The Response, Operability, and Type of
Surgery Following Neoadjuvant
Chemotherapy in Sudanese Patients with
Locally Advanced Breast Cancer
Abdelsamie Abdalla Mohamed, Kamal Eldein H. Mohamed, Eltaib A. Saad, and
Shadad M. Mahmoud
Department of Surgery, Faculty of Medicine, University of Khartoum
Abstract
Background:Neoadjuvant chemotherapy (NACT) treatment has become the standard
treatment for locally advanced breast cancer (LABC) in many centers worldwide.
Objectives: This study evaluates the short-term response of patients with LABC to
NACT and its impact on operability and the type of surgery. Patients and Methods:
This is a descriptive analytical hospital-based study including 147 patients with LABC
who were presented to Plastic and Reconstructive Surgery Unit at Soba University
hospital (SUH), between January 2012 and December 2014, and were treated
with NACT. Clinical and pathological responses to neoadjuvant chemotherapy were
evaluated according to Union for International Cancer Control criteria, operability,
and the type of surgery performed was also recorded. Results: All patients were
females, the mean age was 43 ± 7 years, of them 53.7% were pre-menopausal,
51% presented with a breast lump, 19.7% with nipple discharge, and 19% with
skin changes and ulceration. The mean initial tumor size was 7 cm ± SD. Following
NACT, complete clinical response was reported in 30 patients (20.4%), partial clinical
response in 92(62.6%), stable clinical response in 20 (13.6%), and five (3.4%) had
progressive clinical response. Initial smaller tumors (size < 5 cm) showed a better
clinical response to NACT as 76.7% of complete clinical response was achieved.
Pathological complete response was achieved in 25(17%) patients, pathological
partial response in 102(74.1%), and pathological stable disease in 13(8.8%). Following
NACT, breast conserving surgery was performed in 78(53.1%) patients, Modified
Radical Mastectomy in 64(43.5%), 25 of them had Latissimus Dorsi, and five patients
were not offered surgery as they developed progressive disease during the study
period. Conclusion: Following NACT, it was possible to perform surgery in more than
96% of patients with LABC.
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1. Introduction
Neoadjuvant chemotherapy treatment (NACT) is now the standard treatment for
locally advanced breast cancer (LABC) in several centers worldwide [1–3]. It reduces
the size of the primary tumor, thus offering the option of breast-conserving surgery in
patients who couldn’t have this advantage before [4]. By down-staging tumors, NACT
may likely improve available surgical options.
Numerous randomized clinical trials confirmed the equivalence of Neoadjuvant and
adjuvant chemotherapy in terms of disease-free and overall survival rates [5]. Patho-
logical complete response (pCR), which is defined as absence of residual and in-situ
disease in the breast and the axillary nodes, has recently emerged as a powerful
prognostic marker for overall and disease-free survival following NACT [6, 7]. Attaining
a pCR after NACT has been shown by several investigators to be a good marker for
improved long-term outcome [8–10].
LABC is not a usual presentation among females in the Western world; however, in
Sudan, this stage is not only uncommon, but it also more prevalent among younger
patients [11].
2. Objectives
This work aimed to assess the short-term response of Sudanese patients with LABC
to NACT and its impact on operability and the types of the surgery performed.
3. Patients and Methods
This is a descriptive analytical hospital-based study. A consecutive one hundred forty-
seven (147) patients who were presented with LABC to the Plastic and Reconstructive
Surgery Unit at Soba University hospital (SUH) from January 2012 to December 2014
were reviewed. They were assessed initially at SUH and then referred to Radio-isotope
Center, Khartoum (RICK) for receiving NACT. The study was approved by the Scientific
and Research Committee of Soba University hospital (SUH).
LABC is defined as stage IIIA (T0-N2; T1/2-N2; T3-N1/2), stage IIIB (T4, N0-2), and
stage IIIC disease (any T, N3). Patient with early breast cancer (stage I/II), metastatic
breast cancer (stage IV) proven clinically and/or radiologically and those who haven’t
had regular follow-up during the study period in both RICK and SUH were excluded
from study.
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According to the national protocol of Neoadjuvant chemotherapy, the aim of the
treatment was standardized. For patients with operable lesions and not suitable for
breast conserving surgery (BCS), the chemotherapy was delivered until BCS could be
performed. For patients with inoperable lesions, the chemotherapy was delivered until
curative surgery could be achieved.
The clinical response was assessed at the start, after each two cycles and at the
end of the treatment to document and classify the response. Assessment of the clin-
ical response was based on Union for International Cancer control (UICC) criteria with
definitions as follows: complete response (CR) = complete clinical resolution of tumor;
partial response (PR) = 50% or greater diminution of bi-dimensional tumor; minimal
response (MR) = 25% to 50% diminution of tumor; stable disease (SD) = no more than
25% increase or decrease in tumor size; progressive disease (PD) = more than 25%
increase in tumor [12].
The pathological response was also assessed. Complete pCR was defined as a com-
plete disappearance of invasive breast cancer in the final histological specimen of the
primary tumor. Partial pathological response was defined as a reduction of more than
50% of the initial tumor size, whereas stable pathological disease was defined as
a reduction of less than 50% of the initial tumor size, and progressive disease was
defined as any increase in initial tumor size during cycles of chemotherapy [12]. Data
were processed and analyzed using the SPSS software package (version 21 windows).
To determine the statistical significance of differences, the Pearson test was used and
probability test (P-value)with p< 0.05was considered as significant at 95% confidence
interval.
4. Results
One hundred forty-seven (147) patients receiving neoadjuvant chemotherapy for LABC
were reviewed. All were females, themean age of the patients at the time of diagnosis
was 43 ± 7 years and 79 patients (53.7%) were pre-menopausal. More than half of
the patients (51%) were presented with a breast lump, 29(19.7%) patients had nipple
discharge as a chief complaint, whereas 28(19.0%) were presented initially with skin
changes and ulcers and 15 patients (10.2%) were presented primarily with axillary
changes and swelling. The mean tumor diameter measured clinically before neoadju-
vant chemotherapy was 7 ± 3 cm (range 3–15 cm). Tumor stage and nodal status were
summarized in (Tables 1 and 2, respectively). No association was found between age
and tumor size (P = 0.11); however, a significant association was observed between
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age and nodal status (P = 0.0002) with 53% of those aging more than 45 years having
a late nodal stage (N2 and N3). Regarding histopathological type of the tumors, 132
patients (88.2%) had invasive ductal carcinoma (IDC) and only 15 patients had invasive
lobular carcinoma. Other less common histopathological variants were not reported
in this series. Estrogen receptors (ER) showed positivity in 80 patients (54.4%) with
55(68.8%) of those with positive ER being below 45 years of age, and progesterone
receptors being positive in 78 patients (45%).
Based on clinical evaluation and echocardiographic findings, patients were classified
into three groups. Group A consisted of 52 patients who received 5-Fluorouracil
500mg/m2 I.V, Adiramycin (Doxorubicin) 50mg/m2 I.V, and Cyclophosphamide
500mg/m2 (FAC) for six cycles on a 21-day period, followed by Paclitoxel800 mg/m2
for 12 weeks; group B includes 47 patients who were treated with the 5-Flurouracil
500mg/m2 I.V, epirubricin90mg/m2 I.V, and Cyclophosamide 600mg/m2 (FEC) for four
cycles with three weeks off, and then they received Paclitaxel 100mg/m2 for six
weeks; group C were patients who received doxorubicin 600mg/m2 Cyclophosamide
600mg/m2 I.V and Taxanes (Doxetaxel) 100mg/m2(TAC) regimen and included
patients with cardiac diseases based on echocardiography reports in whom other
regimens were contraindicated. In addition, Prednisolone, antiemetic, and antibiotics
were given when they were clinically indicated.
Thirty (20.4%) patients achieved a clinical complete response (CR). Complete clinical
response (CR) was associated significantly with initial tumor sizes; 56.7% of CR was
achieved in patients with tumor stages (T1 and T2 with tumor size < 5 cm). Partial
response was observed in 92 (62.6%) patients, while static response was achieved
in 20 (13.6%) patients, and five (3.4%) patients had developed a progressive dis-
ease (Table 3). Clinical response was not found to be affected by the age and tumor
histopathology type. Complete pathological response (pCR) was achieved in 25 (17%)
patients in whom no residual disease was seen in postoperative pathological speci-
mens. A significant association was found between pCR and nodal disease and nega-
tivity of ER (P < 0.001 in both) (Table 4).
The type of chemotherapy regimen used was neither found to affect clinical
response nor pathological response (P-values were 0.196 and 0.087. respectively).
Following NACT, BCS was performed in 78 patients (53.1%) who had sufficient
reduction to allow BCS, while 64 (43.5%) patients had modified radical mastectomy,
and in 25 patients (39.1%) Latissimus Dorsi flap (LD) was used to close the defect
followingmastectomy,myo-cutaneous flap in 16 patients andmuscle flap in 9 patients.
A curative surgery could not be achieved in five patients who had developed a
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T 1: Relation between age with initial tumor size (T stage) (n = 147).
Age (years) Initial tumor Size (T stage)*
T1 T2 T3 T4 Total
< 35 1 4 16 5 26
35–45 0 10 21 21 52
> 45 2 13 41 13 69
Total 3 27 78 39 147
Note: *P = 0.11 (> 0.05).
T 2: Relation between age with nodal status (N stage) (n = 147).
Age (years) Nodal status (N stage)*
N0 N1 N2 N3 Total
< 35 0 13 6 7 26
35–45 7 6 32 7 52
> 45 3 29 28 9 69
Total 10 48 66 23 147
Note: *P = 0.0002 (< 0.05).
T 3: Association between clinical response and initial tumor size (T stage) (n = 147).
Clinical Response
Complete Partial Stable Progressive Total
Initial tumor size
(in cm)* T1 < 2
2 1 0 0 3
T2 2–5 15 10 2 0 17




1 24 9 5 39
Total 30 92 20 5 147
Note: *P < 0.001.
T 4: Association between pathological complete response (pCR) and nodal status and ER status (n =
147).
Pathological Response
Complete Partial Stable Total
Nodal Status* N0 7 3 0 10
N1 10 32 6 48
N2 5 58 3 66
N3 3 16 4 23
Total 25 109 13 147
ER Status** Positive 3 72 6 83
Negative 22 37 7 64
Total 25 109 13 147
Note: *P < 0.001; **P < 0.001.
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progressive disease during the course of neoadjuvant therapy. Hormonal therapy
was given to all patients with positive ER receptors.
5. Discussion
NACT permits breast conservation in some patients whowould otherwise require mas-
tectomy [12]. The median age of patients in this study was 43 years and 42% of the
patients were premenopausal, which is comparable to other reports [13–15].
The average number of NACT cycles ranged from four to six cycles depending on
patient’s response. However, the literature reported considerable variations in num-
bers of cycles of chemotherapy that are usually given in neoadjuvant setting [16, 17].
Three regimens of NACT were employed in this study. However, both clinical and
pathological responses were not found to be affected by the type of regimen used
(P-values are 0.196 and 0.087, respectively); this is similar to many series [18, 19], in
contradiction to others that showed a better response with Taxanes-based regimens
[20, 21].
Complete pathological response (pCR) was achieved in 17%, which is in the range of
other series [18, 22], although significant variations exist in pCR values in the literature
ranging from 4% to 40% [23–25]. These variations could be attributable to the use of
different chemotherapy regimens and or the ethnical and racial differences [26, 27].
Age and family history were not associated with complete pathological response in
this series, which is in line with what was reported in the previous studies [28–30]. On
the other hand, the authors found an association between the nodal stage and pCR
(P < 0.001) as the late nodal disease (N2, N3) was associated with poor pathological
response, a finding which is similar to what was found by many other workers [30, 31].
Complete clinical response (CR) was achieved in 20.4% of the patients; it was sig-
nificantly associated with initial tumor size (T stage) as 56.7% of complete clinical
response was observed among patients with an initial tumor size of less than 5 cm (T1
and T2) (P = 0.001). These findings are in agreement with previous reports that proved
better clinical responses with smaller tumors [27, 29]. Clinical response was not found
to be affected by the age and tumor histopathology type which is comparable to the
previous series [29, 30].
Estrogen receptor (ER) status was associated with a better pCR, as 65% of patients
with pCR had a negative ER (P < 0.001) in keeping with previous reports [31, 32];
however, this finding disagrees with other reports that found a better pCR with ER-
positive tumors [13]. Nevertheless, there is an evidence to suggest that ER-negative
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tumors are more likely to achieve better pCR, following NACT in comparison to ER-
positive ones, as an inverse relationship exists between ER expression and tumor
proliferation; with ER-positive cancers showing a low proliferation rate, whereas ER-
negative breast cancers having a high proliferation rate, which is correlated with a
better short-term response to NACT [29, 30].
Seventy-eight (53.1%) patients had achieved a sufficient clinical down-staging to
allow BCS; these results are quite comparable with other international reports [33–
35], but higher than that reported previously in one study from Sudan (33.3%) [13]. In
fact, the literature has reported different rates of BCS after NACT ranging from 16%
to 80% [15]. These variations could be attributable to the differences in the types
of chemotherapy regimens used, the studied population, and the study designs [36].
Nevertheless, there are certain factors that predict eligibility of a conserving surgery
after NACT, with the tumor size being the most important one [37]. It is interesting
to note that some workers have designed validated nomograms to predict the prob-
ability of residual tumor size and eligibility for a conserving surgery after NACT; these
nomograms would be useful when counseling patients about treatment options [37].
To appreciate the findings of this study, some limitations have to be addressed;
the authors had a short-term follow-up period so they could not assess the mid- and
long-term effects of NACT. Besides, the study was conducted in only one center, and
further prospective multi-center studies are recommended to ascertain the findings of
this study.
6. Conclusion
NACT has shown satisfactory short-term results in Sudanese patients with LABC as it
can reduce the tumor size rendering initially inoperable tumors to be operable, and it
can also increase the chance of BCS in other patients with operable tumors that were
initially not suitable for conserving surgery. Further studies to assess the long-term
effects of NACT on disease recurrence and survival rates are recommended.
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